Mr. DeLuccia is co-founder of our company, and currently serves as Executive Chairman and as a director. From January 2010 to March 2014, Mr. DeLuccia served as co-founder and Managing Partner of our Company. From 2004 to 2009 Mr. DeLuccia served in several capacities at MacroChem, a development-stage, publicly traded pharmaceutical company using topical drug delivery technology for products in dermatology, podiatry, urology and cancer, including roles as Chairman, President and Chief Executive Officer, and as director. Mr. DeLuccia also has served as President and Chief Executive Officer of Immunomedics, Inc., a publicly-traded biopharmaceutical company focused on antibody-based therapeutic products and diagnostic imaging for cancer and infectious diseases and as President of Sterling Winthrop, Inc. (or Sterling Winthrop) (as an independent corporation and then as subsidiary of Eastman Kodak), and subsequently, upon acquisition, the U.S. subsidiary of Sanofi-Aventis (or Sanofi). Mr. DeLuccia currently serves as a member of the board of directors of IBEX Technologies Inc. (TSX Venture Exchange: IBT), a Canadian biopharmaceutical company engaged in the production and sale of proprietary enzymes for use as reagents for hemostasis monitoring devices. Mr. DeLuccia began his career as a pharmaceutical sales representative for Pfizer, Inc. (or Pfizer) and progressed to Director of Marketing, Pfizer Laboratories Division and to Vice President Marketing and Sales Operations for Pfizer's Roerig Division. Mr. DeLuccia received a Bachelor of Business Administration with a concentration in Marketing and a Master's Degree in Business Administration, both from Iona College.
Mr. Luci co-founded Dipexium Pharmaceuticals and currently serves as President & Chief Executive Officer and is a member of the board of directors. Prior to co-founding Dipexium Pharmaceuticals, from 2007 to January 2010, Mr. Luci served as a member of the board of directors of Access Pharmaceuticals, Inc., where he also served as Chairman of the Audit Committee and Chairman of the Compensation Committee as well as serving in a consulting capacity following the acquisition of MacroChem Corporation. From December 2007 through February 2009, Mr. Luci also served as a member of the board of directors and in several management capacities of MacroChem, including President, Chief Financial Officer and General Counsel. Prior to that, Mr. Luci served as Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc., an international biopharmaceutical company engaged in the development, marketing and commercialization of oncology products. Mr. Luci created and managed Bioenvision's principal executive offices located in New York, New York as well as its satellite office located in Tokyo, Japan. Mr. Luci was instrumental in creating Bioenvision's international commercial enterprise; managed the worldwide development of Evoltra (clofarabine) as a member of the product's Joint Steering Committee in with senior executives of Genzyme Corporation; and orchestrated, structured and negotiated the sale of Bioenvision to Genzyme for $345 million in 2007. Mr. Luci began his career with Ernst & Whinney LLP (now Ernst &Young LLP) in New York as a certified public accountant working in the Healthcare Practice Group. He later practiced corporate law at Paul Hastings LLP in New York for eight years, where his practice encompassed all aspects of public and private mergers and acquisitions, contract negotiations, corporate finance, restructurings and private equity transactions, with a core focus in the healthcare indust ry. Mr. Luci graduated from Bucknell University with a degree as a Bachelor of Science in Business Administration with a concentration in Accounting and graduated with honors from Albany Law School of Union University where he served as Managing Editor of the Journal of Science & Technology. Mr. Luci became a certified public accountant in the State of Pennsylvania in 1990 (inactive) and is a member of the New York State Bar Association.
Mr. Shawah serves as our Chief Accounting Officer and Treasurer. From 2005 to 2013, Mr. Shawah served as a Vice President of Baldwin Pearson & Co., Inc. focusing on structuring transactions in the commercial and industrial real estate market in Fairfield County, Connecticut, as well as financial reporting responsibility. Prior to that, Mr. Shawah held financial management positions at CC1 Inc., Victorinox/Swiss Army Brands and Grace Cocoa, a division of W.R. Grace. His responsibilities at these firms included accounting, financial reporting, and foreign currency transactions. Mr. Shawah is a certified public accountant in the Commonwealth of Pennsylvania (inactive) and spent the first five years of his career in the audit division of Arthur Andersen LLP. Mr. Shawah received a Bachelor of Science degree in Business Administration with a concentration in accounting from Bucknell University.